Grail, a US spinout from Illumina that is developing blood-based cancer detection tests, is considering a $500 million Hong Kong IPO. Last year, Grail completed a $900 million Series B fundraising, the largest ever. In June, Grail merged with Cirina, a …
( read original story …)